Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012

April 2012 | 11 pages | ID: CA2353AC7FDEN
ResearchInChina

Abstracts

Chongqing Zhifei Biological Products Co., Ltd (Website：www.zhifeishengwu.com; Code：300122.SZ), hereinafter referred to as Zhifei Biological, was established in 1995 with the registered capital of RMB 360 million. Listed on the GEM in Sep. 2010, Zhifei Biological is mainly engaged in the development and management of biological technology. Its prime operating businesses include the R & D, production and sales of vaccines and biological products. Its independent products are: Group A and Group C Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 Meningococcal Polysaccharide Vaccine, Mycobacterium vaccine for Injection, etc, Vaccae has passed GMP certification on Mar.23, 2011; exclusive purchase agent products are: Hib vaccine, Hepatitis A (Live) Vaccine], etc.

Contents

1 PROFILE

2 OPERATION

3 REVENUE STRUCTURE

4 GROSS MARGIN

5 CLIENT

6 R&D AND INVESTMENT

Selected Charts

SELECTED CHARTS

Main Products of Zhifei Biological and Its Subsidiaries
Revenue and Profit of Zhifei Biological, 2007-2012
Revenue Breakdown of Zhifei Biological by Products, 2010-2011
Revenue Structure of Zhifei Biological by Products, 2007-2011
Lot Release Quantity and Proportion of Zhifei Biological by Products, 2011
Revenue Breakdown of Zhifei Biological by Region, 2009-2011
Revenue Structure of Zhifei Biological by Region, 2009-2011
Gross Margin of Zhifei Biological by Products, 2007-2011
Zhifei Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
R&D Expenditure and Its Proportion to Revenue of Zhifei Biological, 2008-2011
New Vaccine Schedule of Zhifei Biological, 2011-2013